CAR-T Player Arcellx Raises $123M Via Initial Public Offering, Opens Trading At $19


CAR-T company Arcellx Inc ACLX priced its IPO at $15 per share, raising $123.8 million at the low end of the Company’s proposed range of $15 - $17.

  • The Company offered 8.3 million shares during the initial public offering.
  • Arcellx's lead ddCAR candidate, CART-ddBCMA, is in Phase 1 development for relapsed or refractory (r/r) multiple myeloma (MM). 
  • Arcellx plans to initiate a Phase 2 trial of CART-ddBCMA for treatment of r/r MM in late 2022 and pursue the development of the candidate in earlier lines of therapy.
  • In 2020, the Company showed its lead BCMA-targeting CAR-T for multiple myeloma shrunk tumors in six out of six patients, with four of them experiencing a stringent complete response.
  • The latest results, presented at ASH last year, showing 19 out of 19 patients saw their tumors shrink, with 13 seeing a stringent complete response. Sixteen patients were still responding after 21 months.
  • Arcellx will list on the NASDAQ under the symbol ACLX. 
  • BofA Securities, SVB Leerink, Barclays, and William Blair acted as joint bookrunners on the deal.
  • Price Action: ACLX shares opened for trade at $19.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareFinancingOfferingsSmall CapGeneralBriefsPhase 1 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!